StemCellPatents.com Newsletter

Hello ,

Last week a paper was published describing that treated with the proteosome inhibitor Velcade could actually sensitize quiescent CML progenitors to killing by natural killer cells.  This is important since CML is one of the situations where immunological control of cancer has been well documented.

Two patents in the area of stem cells were issued last week.  # 7,435,718 discloses compositions of matter for antagonizing CXCR4 and # 7,435,592 covers T cells activated with anti-CD3 and anti-CD28 !  No joke !  this patent could be very useful given that anti-CD3 and anti-CD28 are the main ways of activating human T cells.

Compositions for allogeneic cell therapy     Patent Number: 7,435,592 Assignee | Inventor This patent covers a composition of activated T cells, either autologous or allogeneic.  It is very interesting since the way the claims issued, it covers pretty much any T cell that has been activated by ligation of CD3 and CD28 (the most common way of activating T cell cells).  The first independent claim covers a...[Read More] Ask a question OR leave your comments.

Sensitizing CML Precursors to GVL Sunday October 19th, 2008 @ 12:42:24 EST Bethesda, Maryland - Chronic myeloid leukemia (CML) is a cancer of the myeloid committed stem cell, which is caused primarily by the oncogenic chimeric protein BCR-ABL.  Immune responses are known to control progression of CML.  For example, patients with CML taking interferon that have higher NK cell...[Read More] Ask a question OR leave your comments. Read more StemCellPatents.com News

RMSC 2008 World Congress (2-4 December 2008)
The 3rd Annual Stem Cells World Congress (20-22 January 2009)
The Stem Cell Meeting (March 2009)

RECENTLY ADDED PATENTS     Mammary stem cell marker (7,563,619) Assignee | Inventor | Ask a question OR leave your comments     Soft tissue repair and regeneration using postpartum-derived cells (7,560,276) Assignee | Inventor | Ask a question OR leave your comments     Compositions and methods for generating skin (7,560,275) Assignee | Inventor | Ask a question OR leave your comments     Method for reducing neuronal degeneration so as to ameliorate the effects of injury or disease (7,560,102) Assignee | Inventor | Ask a question OR leave your comments     Human cord blood derived unrestricted somatic stem cells (USSC) (7,560,280) Assignee | Inventor | Ask a question OR leave your comments     Human cord blood derived unrestricted somatic stem cells (USSC) (7,556,801) Assignee | Inventor | Ask a question OR leave your comments     Dedifferentiated, programmable stem cells of monocytic origin, and their production and use (7,553,663) Assignee | Inventor | Ask a question OR leave your comments     Stromal antigen-presenting cells and use thereof (7,553,661) Assignee | Inventor | Ask a question OR leave your comments     Directed in vitro differentiation of marrow stromal cells into neural cell progenitors (7,547,545) Assignee | Inventor | Ask a question OR leave your comments     Progenitor cells from wharton's jelly of human umbilical cord (7,547,546) Assignee | Inventor | Ask a question OR leave your comments     View all 1436 Stem Cell Patents on StemCellPatents.com

LATEST NEWS     Leptin Blocks T Regulatory Cell Expansion August 23rd, 2009     Mechanism of Multiple Sclerosis Stem Cell Therapy July 24th, 2009 : 2 Comments     Lithium for Treatment of Multiple Sclerosis July 15th, 2009     Treatment of Degenerative Disc Disease by Bone Marrow Stem Cells July 9th, 2009 : 2 Comments     Apoptotic Cells Secrete Angiogenic Factors June 27th, 2009     Read more news on StemCellPatents.com

LATEST JOBS POSTS     View the StemCellPatents.com Job Board

Thanks again for your help in supporting StemCellPatents.com.

We welcome your comments and suggestions! Tell us here.

Media Partnerships (NEW)

(BETA)